Guardant Health (5GH) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5GH Analyst Ratings

Strong Buy

21 Buy

0 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Guardant

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5GH Stock 12 Month Forecast

Average Price Target

€164.23

▲(29.81% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is €164.23 with a high forecast of €184.33 and a low forecast of €107.17. The average price target represents a 29.81% change from the last price of €126.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","185":"€185","71.75":"€71.8","109.5":"€109.5","147.25":"€147.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":184.33464245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€184.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":164.23406903555556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€164.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.17130375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€107.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,71.75,109.5,147.25,185],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.36,139.12728018846155,142.8945603769231,146.66184056538464,150.42912075384615,154.1964009423077,157.96368113076923,161.73096131923077,165.4982415076923,169.26552169615383,173.03280188461537,176.8000820730769,180.56736226153845,{"y":184.33464245,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.36,137.58108223350428,139.80216446700857,142.02324670051283,144.24432893401712,146.46541116752138,148.68649340102564,150.90757563452993,153.1286578680342,155.3497401015385,157.57082233504275,159.791904568547,162.0129868020513,{"y":164.23406903555556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.36,133.19163875,131.0232775,128.85491625,126.68655500000001,124.51819375000001,122.3498325,120.18147125000002,118.01311000000001,115.84474875000001,113.6763875,111.50802625,109.339665,{"y":107.17130375,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.36,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€184.33

Average Price Target€164.23

Lowest Price Target€107.17

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Larew

William Blair

―

Buy

―

Reiterated

08/25/26

Guardant Health: Patent Ruling Seen as Manageable Overhang, Analyst Maintains Buy Rating on Favorable Risk–Reward

David Westenberg

Piper Sandler

€165.47

Buy

30.79%

Upside

Reiterated

08/24/26

Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Bradley Bowers

Mizuho Securities

€171.47

Buy

35.53%

Upside

Reiterated

08/04/26

Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)

Kallum Titchmarsh

Morgan Stanley

€150.04→€158.61

Buy

25.37%

Upside

Assigned

08/04/26

Guardant Health price target raised to $185 from $175 at Morgan StanleyGuardant Health price target raised to $185 from $175 at Morgan Stanley

Casey Woodring

J.P. Morgan

€167.19

Buy

32.14%

Upside

Reiterated

08/04/26

J.P. Morgan Sticks to Its Buy Rating for Guardant Health (GH)

Mason Carrico

Stephens

€167.19

Buy

32.14%

Upside

Reiterated

08/04/26

Stephens Remains a Buy on Guardant Health (GH)

Daniel Arias

Stifel Nicolaus

€111.46→€154.33

Buy

21.98%

Upside

Reiterated

08/03/26

Guardant Health price target raised to $180 from $130 at StifelGuardant Health price target raised to $180 from $130 at Stifel

Kyle Mikson CFA

Canaccord Genuity

€175.76

Buy

38.92%

Upside

Reiterated

08/02/26

Guardant Health: Buy Rating Reiterated as Strong Q2 Results, Raised 2026 Outlook Support Unchanged $205 Price Target

Subbu Nambi

Guggenheim

€162.9

Buy

28.75%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Guardant Health (NASDAQ: GH) and Cardinal Health (NYSE: CAH)

Daniel Brennan

TD Cowen

€171.47→€180.05

Buy

42.31%

Upside

Assigned

07/31/26

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Regeneron (REGN)

Dan Leonard

RBC Capital

€158.61→€171.47

Buy

35.53%

Upside

Assigned

07/31/26

Guardant Health (GH) Receives a Buy from RBC Capital

Luke Sergott

Barclays

€128.61→€171.47

Buy

35.53%

Upside

Reiterated

07/31/26

Barclays Sticks to Their Buy Rating for Guardant Health (GH)

Michael Ryskin

Bank of America Securities

―

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Mark Massaro

BTIG

€162.9→€167.19

Buy

32.14%

Upside

Reiterated

07/31/26

Analysts Are Bullish on These Healthcare Stocks: PTC Therapeutics (PTCT), Guardant Health (GH)

Evie Koslosky

Goldman Sachs

€158.61→€180.05

Buy

42.31%

Upside

Assigned

07/31/26

Guardant Health price target raised to $210 from $185 at Goldman SachsGuardant Health price target raised to $210 from $185 at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Larew

William Blair

―

Buy

―

Reiterated

08/25/26

Guardant Health: Patent Ruling Seen as Manageable Overhang, Analyst Maintains Buy Rating on Favorable Risk–Reward

David Westenberg

Piper Sandler

€165.47

Buy

30.79%

Upside

Reiterated

08/24/26

Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Bradley Bowers

Mizuho Securities

€171.47

Buy

35.53%

Upside

Reiterated

08/04/26

Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)

Kallum Titchmarsh

Morgan Stanley

€150.04→€158.61

Buy

25.37%

Upside

Assigned

08/04/26

Guardant Health price target raised to $185 from $175 at Morgan StanleyGuardant Health price target raised to $185 from $175 at Morgan Stanley

Casey Woodring

J.P. Morgan

€167.19

Buy

32.14%

Upside

Reiterated

08/04/26

J.P. Morgan Sticks to Its Buy Rating for Guardant Health (GH)

Mason Carrico

Stephens

€167.19

Buy

32.14%

Upside

Reiterated

08/04/26

Stephens Remains a Buy on Guardant Health (GH)

Daniel Arias

Stifel Nicolaus

€111.46→€154.33

Buy

21.98%

Upside

Reiterated

08/03/26

Guardant Health price target raised to $180 from $130 at StifelGuardant Health price target raised to $180 from $130 at Stifel

Kyle Mikson CFA

Canaccord Genuity

€175.76

Buy

38.92%

Upside

Reiterated

08/02/26

Guardant Health: Buy Rating Reiterated as Strong Q2 Results, Raised 2026 Outlook Support Unchanged $205 Price Target

Subbu Nambi

Guggenheim

€162.9

Buy

28.75%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Guardant Health (NASDAQ: GH) and Cardinal Health (NYSE: CAH)

Daniel Brennan

TD Cowen

€171.47→€180.05

Buy

42.31%

Upside

Assigned

07/31/26

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Regeneron (REGN)

Dan Leonard

RBC Capital

€158.61→€171.47

Buy

35.53%

Upside

Assigned

07/31/26

Guardant Health (GH) Receives a Buy from RBC Capital

Luke Sergott

Barclays

€128.61→€171.47

Buy

35.53%

Upside

Reiterated

07/31/26

Barclays Sticks to Their Buy Rating for Guardant Health (GH)

Michael Ryskin

Bank of America Securities

―

Buy

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Mark Massaro

BTIG

€162.9→€167.19

Buy

32.14%

Upside

Reiterated

07/31/26

Analysts Are Bullish on These Healthcare Stocks: PTC Therapeutics (PTCT), Guardant Health (GH)

Evie Koslosky

Goldman Sachs

€158.61→€180.05

Buy

42.31%

Upside

Assigned

07/31/26

Guardant Health price target raised to $210 from $185 at Goldman SachsGuardant Health price target raised to $210 from $185 at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months

Luke SergottBarclays

Success Rate

11/15 ratings generated profit

Average Return

+31.33%

Copying Luke Sergott's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +31.33% per trade.

1 Year

William BonelloCraig-Hallum

Success Rate

14/14 ratings generated profit

Average Return

+147.23%

Copying William Bonello's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +147.23% per trade.

2 Years

William BonelloCraig-Hallum

Success Rate

14/14 ratings generated profit

Average Return

+313.41%

Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +313.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5GH Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5GH has received 50 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 5GH average Analyst price target in the past 3 months is 164.23.

Each month's total comprises the sum of three months' worth of ratings.

5GH Financial Forecast

5GH Earnings Forecast

Next quarter’s earnings estimate for 5GH is -€0.65 with a range of -€0.79 to -€0.55. The previous quarter’s EPS was -€0.77. 5GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5GH has Performed in-line its overall industry.

5GH Sales Forecast

Next quarter’s sales forecast for 5GH is €300.20M with a range of €293.58M to €307.80M. The previous quarter’s sales results were €287.20M. 5GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5GH has Performed in-line its overall industry.

5GH Stock Forecast FAQ

What is DE:5GH’s average 12-month price target, according to analysts?

Based on analyst ratings, Guardant Health’s 12-month average price target is 164.23.

What is DE:5GH’s upside potential, based on the analysts’ average price target?

Guardant Health has 29.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Guardant Health a Buy, Sell or Hold?

Guardant Health has a consensus rating of Strong Buy, which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.

What is Guardant Health’s share price target?

The average share price target for Guardant Health is 164.23. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €184.33 ,and the lowest forecast is €107.17. The average share price target represents 29.81% Increase from the current price of €126.52.

What do analysts say about Guardant Health?

Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Guardant Health?

To buy shares of DE:5GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Guardant Health (5GH) Stock Forecast & Price Target

5GH Analyst Ratings

5GH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Guardant Health

5GH Analyst Recommendation Trends

5GH Financial Forecast

5GH Earnings Forecast

5GH Sales Forecast

5GH Stock Forecast FAQ

Detailed List of Analyst Forecasts